A securities class action has been filed against Aldeyra Therapeutics, Inc. (ALDX) on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics securities between November 3, 2023 through March 16, 2026. This case has been filed in the USDC – MA.
The complaint alleges Aldeyra Therapeutics misled Investors regarding its lead drug candidate during the class period, defendants failed to disclose that: (1) the results of the reproxalap clinical trials were inconsistent; (2) the inconsistency of the results rendered any positive findings from these trials unreliable and not meaningful; and (3) as a result, defendants’ statements about Aldeyra’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On March 17, 2026, the Company filed with the SEC a current report on Form 8-K, announcing receipt of the 2026 Complete Response Letter, stating that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.” The 2026 Complete Response Letter also stated that the “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that “the totality of evidence from the completed clinical trials does not support the effectiveness of the product.”
On this news, the price of Aldeyra stock went down by $2.99, or approximately 70.7%, to close at $1.24 per share on March 17, 2026.